LGND News and Press, Ligand Pharmaceuticals Incorporated From 03/06/20

Quick Take NLS Pharmaceutics ( NLSP ) has filed to raise $40.25 million in an IPO of its common stock, according to an F-1 registration statement . The company is advancing a pipeline of drug candidates for the treatment of various central nervous system disorders. NLSP expects to begin...

Ligand Pharmaceuticals ( LGND +11.2% ) surges after raising its 2020 earnings and revenue guidance , citing higher material sales of its Captisol technology stemming from multiple recent orders for Captisol to be used with the investigational compound remdesivir. More news on: Ligand Ph...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133 million and diluted EPS to be $3.62, up from previous guidance for total revenues of approxim...

Transaction Expected to be Immediately Accretive to Revenues and Adjusted EPS Slides to accompany this announcement are posted to Ligand.com Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement whereby Ligand will acquire the core assets o...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2019 Q4 earnings Read more ...

Ligand Pharmaceuticals, Inc. (LGND) Q4 2019 Results Conference Call February 6, 2020 04:30 PM ET CompanyParticipants Patrick O'Brien - Supervisor of Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance and Chief Financial Of...

Image source: The Motley Fool. Ligand Pharmaceuticals Inc   (NASDAQ: LGND) Q4 2019 Earnings Call Feb 6, 2020 , 4:30 p.m. ET Operator Continue reading

Ligand Pharmaceuticals (NASDAQ: LGND ): Q4 Non-GAAP EPS of $0.71; GAAP EPS of -$0.43. More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Healthcare stocks news, Read more ...

Conference Call and Webcast with Slides Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2019, and provided an operating forecast and program updates. Ligand manag...

Ligand Pharmaceuticals (NASDAQ: LGND ) is scheduled to announce Q4 earnings results on Thursday, February 6th, after market close. The consensus EPS Estimate is $0.12 (-92.9% Y/Y) and the consensus Revenue Estimate is $25.3M (-57.5% Y/Y). Over the last 2 years, LGND  has beaten EP...